AZN: AstraZeneca Plc Price-to-Revenue Multiple

Brandmark of AstraZeneca AB (AZN)

The calculated price-to-sales ratio helps identify the overvaluation of AstraZeneca PLC (AZN) assets, based on the high margins of its oncology drugs. Business growth is driven by expansion into biopharmaceuticals and acquisitions. Leadership in the ESG agenda is confirmed by the transition to carbon-negative production. The current metric stands at 4.60, allowing investors to find an optimal entry point into the asset.

Price-to-Revenue Ratio: AstraZeneca (AZN) for 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for AstraZeneca AB (AZN)

- stock price and consensus target price:
Share Price astrazeneca.com|AZN - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization AstraZeneca AB|AZN - Enterprise Value
- book capitalization data:
Book Value per Share AstraZeneca|AZN - Company Book Value|Market Capitalization to Book Value astrazeneca.com|AZN - Cumulative Company Assets
- debt obligations and liquidity statistics:
Aggregate Debt to Capital AstraZeneca PLC|AZN - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital AstraZeneca Corp.|AZN - Company Aggregate Debts|Debts to Book Capitalization AstraZeneca AB|AZN - Company Long-Term Liabilities|Current Liabilities AstraZeneca|Immediate Liquidity astrazeneca.com
- company profitability and valuation multiples indicators:
AZN - Company Net Income|Net Profit Forecast AstraZeneca PLC|AZN - P/E Multiple|Projected Price to Earnings Ratio AstraZeneca Plc|AZN - PEG Multiple|Enterprise Value to EBITDA Ratio AstraZeneca AB|AZN - Operating profit EBITDA|Net earnings per share (EPS TTM) AstraZeneca|AZN - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months astrazeneca.com|AZN - Earnings per share growth in current year|Net earnings per share change forecast for next year AstraZeneca PLC
- total revenue and sales volume data:
AZN - Company Revenue|Company Projected Revenue astrazeneca.com|AZN - P/S Multiple|Forward Price-to-Revenue Multiple AstraZeneca AB
General company analysis:AZN astrazeneca.com
Brand item of AstraZeneca Corp.

AstraZeneca PLC (AZN) is developing a high-tech ecosystem in rare disease therapy and oncology, where revenue growth depends on new drug approvals and regulatory pricing policies. By analyzing the price-to-sales ratio, an investor compares market capitalization with annual turnover to determine the asset's degree of overbought status relative to historical averages and to assess the business's resilience to market corrections.

Who AstraZeneca PLC competes with

lilly.com - Market Cap to Revenue Ratio|P/S Multiple ABBV (AbbVie)|Price-to-Revenue Multiple Novartis Corporation|Merck Sharp & Dohme - P/S Multiple|NVO - P/S Multiple|Amgen Inc. (AMGN) - Price-to-Revenue Ratio|PFE - Price-to-Revenue Coefficient|Market Cap to Revenue SNY|BMY (Bristol Myers Squibb Company) - Market Cap to Sales Volume|Price-to-Revenue Ratio GSK plc (GSK)|TAK (Takeda Pharma) - Market Capitalization-to-Revenue Ratio|P/S Multiple TEVA (Teva Pharmaceutical Industries)|P/S Multiple drreddys.com RDY|VTRS: Market Cap to Revenue|Price-to-Sales Ratio ROIV|ZLAB: P/S Multiple|Price to Sales Bausch Health Corp (BHC)|Price-to-Revenue Ratio Cosmos Health Inc.